BioMarin Pharmaceutical - BMRN Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $107.61
Forecasted Upside: 21.42%
Number of Analysts: 19
Breakdown:
0 Sell Ratings
7 Hold Ratings
12 Buy Ratings
0 Strong Buy Ratings

^$88.63 As of 04/19/2024 01:00 AM ET

▼ -1.44 (-1.60%)

1 month | 3 months | 12 months

Get New BioMarin Pharmaceutical Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for BMRN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMRN

^$107.61

▲ +21.42% Upside Potential

This price target is based on 19 analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $107.61, with a high forecast of $185.00 and a low forecast of $78.00. The average price target represents a 21.42% upside from the last price of $88.63.

Current Consensus is Moderate Buy

The current consensus among 19 contributing investment analysts is to moderate buy stock in BioMarin Pharmaceutical. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
12 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

10/27/2022

0 strong buy ratings
12 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

1/25/2023

0 strong buy ratings
12 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

4/25/2023

0 strong buy ratings
12 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

7/24/2023

0 strong buy ratings
12 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

10/22/2023

0 strong buy ratings
12 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

1/20/2024

0 strong buy ratings
12 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

3/20/2024

0 strong buy ratings
12 buy ratings
7 hold ratings
0 sell ratings

Ratings as of

4/19/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/29/2024	Canaccord Genuity Group	Reiterated Rating	Hold ➝ Hold	$91.00	Low
2/23/2024	Piper Sandler	Lower Target	Overweight ➝ Overweight	$115.00 ➝ $107.00	Low
2/23/2024	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$100.00	Low
2/23/2024	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$100.00	Low
1/30/2024	Robert W. Baird	Lower Target	Outperform ➝ Outperform	$127.00 ➝ $104.00	Low
12/21/2023	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$101.00	Low
11/15/2023	Wells Fargo & Company	Initiated Coverage	Overweight	$100.00	Low
11/7/2023	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$100.00	Low
11/3/2023	BMO Capital Markets	Lower Target	Outperform ➝ Outperform	$102.00 ➝ $100.00	Low
11/2/2023	Cantor Fitzgerald	Lower Target	Overweight ➝ Overweight	$120.00 ➝ $100.00	Low
11/2/2023	Barclays	Lower Target	Overweight ➝ Overweight	$125.00 ➝ $111.00	N/A
11/2/2023	Morgan Stanley	Lower Target	Overweight ➝ Overweight	$125.00 ➝ $117.00	N/A
11/2/2023	Piper Sandler	Lower Target	Overweight ➝ Overweight	$125.00 ➝ $115.00	N/A
11/2/2023	Wedbush	Reiterated Rating	Neutral	$78.00	Low
10/23/2023	Sanford C. Bernstein	Upgrade	Underperform ➝ Market Perform	$82.00	Low
10/16/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$120.00	Low
9/28/2023	Raymond James	Initiated Coverage	Market Perform		Low
9/25/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$140.00	Low
9/18/2023	UBS Group	Initiated Coverage	Buy	$120.00	Low
9/15/2023	Truist Financial	Reiterated Rating	Buy ➝ Buy	$140.00	Low
9/14/2023	Wedbush	Reiterated Rating	Neutral	$71.00 ➝ $78.00	Low
9/13/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$120.00	Low
9/13/2023	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$100.00	Low
9/13/2023	Guggenheim	Reiterated Rating	Buy ➝ Buy	$110.00	Low
8/1/2023	Morgan Stanley	Lower Target	Overweight ➝ Overweight	$129.00 ➝ $125.00	Low
8/1/2023	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform	$100.00	Low
8/1/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$120.00	Low
8/1/2023	Wedbush	Lower Target	Neutral ➝ Neutral	$73.00 ➝ $70.00	Low
8/1/2023	Stifel Nicolaus	Lower Target	Buy ➝ Buy	$118.00 ➝ $108.00	Low
7/27/2023	Scotiabank	Initiated Coverage	Sector Perform	$95.00	Low
7/21/2023	Bank of America	Lower Target	Buy	$185.00	Low
7/5/2023	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$102.00	Low
7/3/2023	Guggenheim	Lower Target		$120.00 ➝ $110.00	Low
6/30/2023	Truist Financial	Boost Target	Buy	$125.00 ➝ $140.00	Low
6/30/2023	Robert W. Baird	Reiterated Rating	Outperform ➝ Outperform	$127.00	Low
6/30/2023	Citigroup	Lower Target	Neutral	$103.00 ➝ $96.00	Low
6/30/2023	500.com	Reiterated Rating	Reiterates		Low
6/30/2023	Wedbush	Boost Target	Neutral	$69.00 ➝ $73.00	Low
4/27/2023	888	Reiterated Rating	Maintains		Low
4/27/2023	Guggenheim	Lower Target		$125.00 ➝ $120.00	Low
4/27/2023	Robert W. Baird	Boost Target		$112.00 ➝ $127.00	Low
3/21/2023	Sanford C. Bernstein	Initiated Coverage	Underperform	$81.00	Low
3/7/2023	BMO Capital Markets	Lower Target	Market Perform	$107.00 ➝ $102.00	Low
2/28/2023	Guggenheim	Reiterated Rating	Buy	$125.00	Low
2/28/2023	Stifel Nicolaus	Boost Target	Buy	$114.00 ➝ $118.00	Low
2/28/2023	Canaccord Genuity Group	Lower Target	Hold	$119.00 ➝ $112.00	Low
2/28/2023	Wedbush	Lower Target	Neutral	$83.00 ➝ $74.00	Low
2/28/2023	Morgan Stanley	Lower Target	Overweight	$132.00 ➝ $131.00	Low
2/28/2023	Credit Suisse Group	Boost Target	Outperform	$110.00 ➝ $127.00	Low
2/22/2023	Avian Securities	Downgrade	Market Perform		Low
2/22/2023	Oppenheimer	Downgrade	Outperform ➝ Market Perform		Low
2/21/2023	Citigroup	Initiated Coverage	Neutral	$116.00	Low
2/3/2023	SVB Leerink	Boost Target	Outperform	$122.00 ➝ $130.00	Low
1/30/2023	BMO Capital Markets	Initiated Coverage	Market Perform	$107.00	Low
1/24/2023	Morgan Stanley	Boost Target	Overweight	$113.00 ➝ $132.00	Low
1/18/2023	Canaccord Genuity Group	Initiated Coverage	Hold	$119.00	Low
1/11/2023	Wedbush	Boost Target	Neutral	$74.00 ➝ $83.00	Low
1/9/2023	Guggenheim	Boost Target		$120.00 ➝ $125.00	Low
1/4/2023	Bank of America	Boost Target		$200.00	Low
12/2/2022	Evercore ISI	Boost Target		$130.00	Low
11/29/2022	Jefferies Financial Group	Boost Target	Buy	$100.00 ➝ $120.00	Low
10/31/2022	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$92.00 ➝ $110.00	Low
10/27/2022	Credit Suisse Group	Lower Target	Outperform	$111.00 ➝ $110.00	Low
10/27/2022	Morgan Stanley	Boost Target	Overweight	$111.00 ➝ $113.00	Low
10/24/2022	JPMorgan Chase & Co.	Lower Target	Overweight	$140.00 ➝ $112.00	Low
10/13/2022	Morgan Stanley	Lower Target	Overweight	$117.00 ➝ $111.00	Low
10/13/2022	Royal Bank of Canada	Boost Target	Sector Perform	$90.00 ➝ $95.00	Low
10/12/2022	Cantor Fitzgerald	Boost Target		$110.00 ➝ $115.00	Low
9/28/2022	Stifel Nicolaus	Boost Target		$104.00	Low
9/13/2022	Wedbush	Reiterated Rating	Neutral	$74.00	Low
8/26/2022	Robert W. Baird	Reiterated Rating	Outperform ➝ Outperform	$112.00	Low
8/9/2022	Credit Suisse Group	Boost Target		$111.00	N/A
8/9/2022	Piper Sandler	Boost Target	Overweight	$125.00 ➝ $128.00	Low
8/4/2022	Morgan Stanley	Boost Target	Overweight	$113.00 ➝ $117.00	Low
8/4/2022	SVB Leerink	Boost Target	Outperform	$115.00 ➝ $122.00	Low
8/4/2022	Barclays	Boost Target	Overweight	$112.00 ➝ $125.00	Low
7/12/2022	Cantor Fitzgerald	Initiated Coverage	Overweight	$110.00	N/A
6/28/2022	Robert W. Baird	Reiterated Rating	Outperform ➝ Outperform	$112.00	Low
6/24/2022	Wedbush	Reiterated Rating	Hold	$70.00	Low
6/13/2022	Wedbush	Lower Target	Outperform ➝ Neutral	$146.00 ➝ $70.00	High
6/6/2022	Credit Suisse Group	Boost Target	Outperform	$105.00 ➝ $106.00	High
5/4/2022	Jefferies Financial Group	Reiterated Rating	Buy ➝ Buy	$100.00	Low
5/3/2022	Stifel Nicolaus	Reiterated Rating	Buy	$96.00	Low
4/28/2022	Wedbush	Lower Target		$155.00 ➝ $147.00	High
4/25/2022	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$96.00 ➝ $113.00	Medium
4/12/2022	Morgan Stanley	Boost Target	Equal Weight	$90.00 ➝ $96.00	Low
2/24/2022	Wedbush	Reiterated Rating	Outperform	$155.00	Medium
2/24/2022	Piper Sandler	Boost Target	Overweight	$121.00 ➝ $125.00	High
2/18/2022	Morgan Stanley	Reiterated Rating	Hold	$90.00	N/A
1/10/2022	Truist Financial	Boost Target		$125.00 ➝ $135.00	High
12/2/2021	SVB Leerink	Reiterated Rating	Buy		Low
11/23/2021	Robert W. Baird	Boost Target	Outperform	$101.00 ➝ $112.00	Low
11/22/2021	Oppenheimer	Boost Target	Market Perform	$84.00 ➝ $95.00	Low
11/22/2021	Guggenheim	Boost Target	Buy	$103.00 ➝ $120.00	Low
11/22/2021	Credit Suisse Group	Boost Target	Outperform	$100.00 ➝ $105.00	Low
11/22/2021	JPMorgan Chase & Co.	Boost Target	Overweight	$129.00 ➝ $135.00	Low
11/22/2021	Morgan Stanley	Boost Target	Equal Weight	$82.00 ➝ $90.00	Low
11/22/2021	SVB Leerink	Boost Target	Outperform	$112.00 ➝ $115.00	Low
11/22/2021	William Blair	Upgrade	Market Perform ➝ Outperform		Medium
11/15/2021	SVB Leerink	Boost Target	Outperform	$108.00 ➝ $112.00	Low
10/28/2021	Wedbush	Reiterated Rating	Outperform	$152.00	Medium
10/28/2021	Credit Suisse Group	Lower Target	Outperform	$102.00 ➝ $100.00	High
10/28/2021	Piper Sandler	Boost Target	Overweight	$119.00 ➝ $121.00	High
9/14/2021	SVB Leerink	Reiterated Rating	Buy		Low
9/9/2021	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$86.00 ➝ $96.00	High
9/7/2021	Royal Bank of Canada	Reiterated Rating	Hold	$88.00	High
9/7/2021	Wedbush	Reiterated Rating	Buy	$152.00	High
8/30/2021	Wedbush	Boost Target	Outperform	$141.00 ➝ $152.00	Low
7/29/2021	Wedbush	Reiterated Rating	Buy	$141.00	Medium
7/29/2021	Jefferies Financial Group	Initiated Coverage	Buy	$112.00	Medium
7/29/2021	Royal Bank of Canada	Boost Target	Sector Perform	$87.00 ➝ $88.00	High
7/29/2021	Piper Sandler	Boost Target	Overweight	$112.00 ➝ $119.00	Medium
7/16/2021	Wedbush	Reiterated Rating	Buy	$141.00	Medium
7/11/2021	SVB Leerink	Initiated Coverage	Buy	$83.62	Medium
7/2/2021	SVB Leerink	Reiterated Rating	Buy		High
6/29/2021	Wedbush	Reiterated Rating	Buy	$141.00	Low
4/28/2021	Wedbush	Reiterated Rating	Buy	$139.00	Low
4/26/2021	Credit Suisse Group	Initiated Coverage	Outperform	$102.00	Medium
4/19/2021	Morgan Stanley	Lower Target	Equal Weight	$85.00 ➝ $82.00	Low
3/23/2021	Wedbush	Reiterated Rating	Outperform	$139.00	Medium
3/1/2021	Evercore ISI	Upgrade	In-Line ➝ Outperform	$90.00 ➝ $100.00	Low
3/1/2021	Robert W. Baird	Reiterated Rating	Buy		Low
1/11/2021	Robert W. Baird	Boost Target	Positive ➝ Outperform	$100.00 ➝ $110.00	High
11/6/2020	SVB Leerink	Lower Target	Outperform	$113.00 ➝ $108.00	High
9/10/2020	Truist Financial	Lower Target		$130.00 ➝ $125.00	Low
9/10/2020	Wedbush	Reiterated Rating	Buy		High
8/21/2020	Morgan Stanley	Lower Target	Equal Weight	$125.00 ➝ $85.00	Low
8/20/2020	Truist Financial	Lower Target		$143.00 ➝ $130.00	Low
8/20/2020	Oppenheimer	Lower Target		$116.00 ➝ $88.00	Low
8/20/2020	Jefferies Financial Group	Lower Target	Buy	$138.00 ➝ $118.00	Medium
8/20/2020	William Blair	Reiterated Rating	Outperform ➝ Market Perform		Medium
8/19/2020	Citigroup	Downgrade	Buy ➝ Neutral	$148.00 ➝ $86.00	Medium
8/19/2020	Wedbush	Reiterated Rating	Buy	$136.00	Medium
8/19/2020	SVB Leerink	Lower Target	Outperform	$140.00 ➝ $113.00	High
8/19/2020	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$123.00 ➝ $92.00	High
8/19/2020	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$127.00 ➝ $100.00	High
8/14/2020	The Goldman Sachs Group	Boost Target		$172.00 ➝ $218.00	Low
8/6/2020	BMO Capital Markets	Boost Target	Market Perform	$94.00 ➝ $108.00	Low
8/5/2020	Oppenheimer	Initiated Coverage	Hold	$116.00	Low
8/5/2020	Wedbush	Reiterated Rating	Buy	$146.00	Low
8/5/2020	Barclays	Boost Target		$125.00 ➝ $135.00	Low
8/5/2020	Piper Sandler	Boost Target		$120.00 ➝ $133.00	Low
8/5/2020	Credit Suisse Group	Reiterated Rating	Buy	$128.00	Medium
8/5/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$140.00 ➝ $156.00	Low
8/5/2020	SVB Leerink	Boost Target	Outperform	$130.00 ➝ $140.00	Low
7/28/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy	$140.00	Low
7/27/2020	Wedbush	Reiterated Rating	Buy	$145.00	Low
7/24/2020	Robert W. Baird	Boost Target		$125.00 ➝ $140.00	Low
7/8/2020	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$125.00	Low
7/6/2020	Citigroup	Boost Target	Buy	$105.00 ➝ $148.00	Low
6/21/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
6/18/2020	Wedbush	Reiterated Rating	Buy	$145.00	High
6/18/2020	SunTrust Banks	Boost Target		$109.00 ➝ $143.00	Low
6/18/2020	Oppenheimer	Boost Target	Performer	$88.00 ➝ $95.00	High
6/17/2020	SunTrust Banks	Boost Target	Buy	$109.00 ➝ $143.00	Medium
6/10/2020	Bank of America	Boost Target	Buy	$120.00 ➝ $130.00	Low
6/5/2020	Barclays	Boost Target		$105.00 ➝ $125.00	Medium
6/3/2020	Wedbush	Reiterated Rating	Buy	$145.00	Medium
6/1/2020	Credit Suisse Group	Reiterated Rating	Buy	$128.00	Low
5/10/2020	Cfra	Reiterated Rating	Buy	$115.00	Low
5/7/2020	Credit Suisse Group	Reiterated Rating	Buy	$128.00	High
5/1/2020	Wedbush	Reiterated Rating	Outperform	$145.00	Low
5/1/2020	William Blair	Reiterated Rating	Buy		Low
4/30/2020	SunTrust Banks	Lower Target	Buy	$110.00 ➝ $109.00	High
4/30/2020	Nomura	Reiterated Rating	Hold	$77.00	High
4/30/2020	Credit Suisse Group	Lower Target	Outperform	$131.00 ➝ $128.00	High
4/30/2020	Oppenheimer	Reiterated Rating	Hold	$88.00	High
4/6/2020	Wedbush	Reiterated Rating	Buy	$164.00	High
3/24/2020	Wedbush	Reiterated Rating	Outperform		High
3/3/2020	Morgan Stanley	Boost Target	Overweight	$120.00 ➝ $125.00	Low
3/2/2020	Nomura Securities	Reiterated Rating	Hold	$77.00	Medium
3/1/2020	Wedbush	Reiterated Rating	Buy	$164.00	High
2/28/2020	Citigroup	Boost Target		$95.00 ➝ $105.00	Medium
2/28/2020	Barclays	Reiterated Rating	Buy	$100.00	Medium
2/27/2020	Oppenheimer	Boost Target		$88.00 ➝ $80.00	Medium
2/23/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
2/21/2020	Wedbush	Reiterated Rating	Outperform	$158.00 ➝ $175.00	Low
1/27/2020	BMO Capital Markets	Initiated Coverage	Market Perform	$94.00	Medium
1/24/2020	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$111.00 ➝ $113.00	Low
1/21/2020	Wedbush	Reiterated Rating	Buy	$158.00	Low
1/2/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		Low
12/23/2019	Wedbush	Reiterated Rating	Buy	$158.00	N/A
12/17/2019	Wedbush	Reiterated Rating	Buy	$158.00	Low
12/16/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$129.00	Low
12/16/2019	Royal Bank of Canada	Reiterated Rating	Hold	$111.00	Low
12/16/2019	Cowen	Reiterated Rating	Buy	$150.00	Medium
12/13/2019	Robert W. Baird	Reiterated Rating	Buy	$120.00	High
12/11/2019	Bank of America	Reiterated Rating	Buy	$90.00	High
11/27/2019	Barclays	Upgrade	Equal Weight ➝ Overweight	$86.00 ➝ $98.00	Medium
11/22/2019	Wedbush	Reiterated Rating	Buy	$157.00	Low
11/15/2019	William Blair	Reiterated Rating	Buy		Low
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$110.00	Medium
10/30/2019	Citigroup	Reiterated Rating	Buy	$120.00 ➝ $95.00	Low
10/25/2019	Wedbush	Boost Target	Outperform	$128.00 ➝ $152.00	Low
10/24/2019	Nomura Securities	Lower Target		$93.00 ➝ $77.00	Medium
10/24/2019	Barclays	Lower Target	Equal Weight	$95.00 ➝ $86.00	Medium
10/21/2019	Cantor Fitzgerald	Set Target	Buy	$129.00	High
10/16/2019	Bank of America	Initiated Coverage	Buy	$90.00	Low
9/26/2019	Wedbush	Set Target	Buy	$128.00	High
9/13/2019	Piper Sandler Companies	Set Target	Buy	$120.00	Medium
9/13/2019	Stifel Nicolaus	Set Target	Buy	$108.00	Medium
8/5/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$133.00	High
7/10/2019	Wedbush	Reiterated Rating	Outperform	$128.00	Medium
6/19/2019	Wedbush	Reiterated Rating	Outperform	$128.00	Low
6/2/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
5/28/2019	Wedbush	Reiterated Rating	Buy	$128.00	Medium
5/23/2019	Citigroup	Reiterated Rating	Buy ➝ Buy		Low
4/26/2019	Robert W. Baird	Set Target	Buy	$120.00	Low
4/26/2019	Wedbush	Boost Target	Outperform ➝ Outperform	$127.00 ➝ $128.00	Low
4/26/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$131.00	Low

(Data available from 4/19/2019 forward)

News Sentiment Rating

1.07 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

16 very positive mentions
10 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/22/2023

17 very positive mentions
6 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

10/22/2023

6 very positive mentions
14 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

11/21/2023

16 very positive mentions
4 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

12/21/2023

13 very positive mentions
9 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

1/20/2024

25 very positive mentions
12 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/19/2024

29 very positive mentions
27 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

3/20/2024

14 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/19/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Today's Range

Now: $88.63

$88.29

$90.18

50 Day Range

MA: $87.61

$83.81

$92.22

52 Week Range

Now: $88.63

$76.02

$99.56

Volume

1,778,607 shs

Average Volume

1,354,274 shs

Market Capitalization

$16.73 billion

P/E Ratio

100.72

Dividend Yield

N/A

Beta

0.31

Frequently Asked Questions

What sell-side analysts currently cover shares of BioMarin Pharmaceutical?: The following equities research analysts have issued research reports on BioMarin Pharmaceutical in the last twelve months: 500.com Limited, 888 Holdings plc, Bank of America Co., Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Guggenheim, Morgan Stanley, Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Sanford C. Bernstein, Scotiabank, Stifel Nicolaus, StockNews.com, TheStreet, Truist Financial Co., UBS Group AG, Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for BMRN.
What is the current price target for BioMarin Pharmaceutical?: 18 Wall Street analysts have set twelve-month price targets for BioMarin Pharmaceutical in the last year. Their average twelve-month price target is $107.61, suggesting a possible upside of 19.5%. Bank of America Co. has the highest price target set, predicting BMRN will reach $185.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $78.00 for BioMarin Pharmaceutical in the next year.
View the latest price targets for BMRN.
What is the current consensus analyst rating for BioMarin Pharmaceutical?: BioMarin Pharmaceutical currently has 7 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BMRN.
What other companies compete with BioMarin Pharmaceutical?: Other companies that are similar to BioMarin Pharmaceutical include Alnylam Pharmaceuticals, MyoKardia, United Therapeutics, Reata Pharmaceuticals and Ionis Pharmaceuticals. Learn More about companies similar to BioMarin Pharmaceutical.
How do I contact BioMarin Pharmaceutical's investor relations team?: BioMarin Pharmaceutical's physical mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company's listed phone number is (415) 506-6700 and its investor relations email address is [email protected]. The official website for BioMarin Pharmaceutical is www.bmrn.com. Learn More about contacing BioMarin Pharmaceutical investor relations.

BioMarin Pharmaceutical - BMRN Stock Price Target and Predictions

Analyst Price Target for BMRN

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

1.07 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of BioMarin Pharmaceutical?

What is the current price target for BioMarin Pharmaceutical?

What is the current consensus analyst rating for BioMarin Pharmaceutical?

What other companies compete with BioMarin Pharmaceutical?

How do I contact BioMarin Pharmaceutical's investor relations team?